Monday, February 1, 2010

Vertex Upgraded By Oppenheimer -- On Telaprevir's Prospects: "Outperform"


With its 2009 year-end results (and 2010 guidance) due out on Thursday (pre-market) morning, Vertex was just upgraded to "outperform" by Oppenheimer -- per Business Week's online edition:

. . . .An Oppenheimer analyst upgraded the stock of Vertex Pharmaceuticals on the potential of its hepatitis C treatment.

Analyst Dr. Brian Abrahams said Monday that he believes it will be a significant year for the Cambridge, Mass., company, with the experimental drug telaprevir driving its stock.

He upgraded company shares to "outperform" from "perform". . . .

Of course, telaprevir is well-ahead of legacy-Schering-Plough's boceprevir -- in the race for a next-gen Hep C treatment regimen -- on both the timeline-to-approval, and previous Hep C non-responder efficacy measures.

4 comments:

Anonymous said...

http://www.dilbert.com/strips/comic/2010-02-02/

Condor said...

Great one -- with corporate choppers, yet again!

But isn't the currently PC/polite term (in the last line) "little people"? Thanks!

Namaste

Anonymous said...

Since when has the CEO ever cared about the 'little people's' feelings?

Condor said...

Indeed. Well put. [I think a rim-shot ought to follow yours.]

Namaste